Pressure-time-curves with different needles and different needle length using evacuation volumes of 20 and 50 ml

<p><b>Copyright information:</b></p><p>Taken from "Diagnostic outcome of two different CT-guided fine needle biopsy procedures"</p><p>http://www.diagnosticpathology.org/content/2/1/31</p><p>Diagnostic Pathology 2007;2():31-31.</p><p>Published online 23 Aug 2007</p><p>PMCID:PMC2063495.</p><p></p

Pig spleen model – fine needle biopsy: number of harvested cells versus needle type and handling (median and range)

<p><b>Copyright information:</b></p><p>Taken from "Diagnostic outcome of two different CT-guided fine needle biopsy procedures"</p><p>http://www.diagnosticpathology.org/content/2/1/31</p><p>Diagnostic Pathology 2007;2():31-31.</p><p>Published online 23 Aug 2007</p><p>PMCID:PMC2063495.</p><p></p> Squares = YN without negative pressure, tri-angles = YN using 20 ml aspiration volume, diamonds = YN using 50 ml aspiration volume, circles = Rotex Screw Needle

Univariate regression analysis of protein analytes versus lung function parameters in COPD subjects with and without metabolic syndrome.

<p>Significance (<i>p</i> values) and effect sizes (spearman correlation) are listed for biomarker associations with lung function parameters. Interaction <i>p</i> values indicate significance of differences in biomarker associations with lung function parameters, between metabolic syndrome and non- metabolic syndrome groups.</p

Overview of data analysis on COPD cohort.

<p>Overview of data analysis on COPD cohort.</p

Multivariate analysis of protein analyte data for COPD subjects.

<p>Spearman correlation and adjusted R squared values were computed using test set samples, in a 5-fold nested cross-validation scheme, averaged over 10 random seeds. R squared values were adjusted for the number of predictor terms in the model.</p

Protein analyte differences between COPD and control disease severity groups.

<p>Data are expressed as median (interquartile range) in ng/ml for individual analytes, except for Fibrinogen which is in mg/dl.</p><p>All analyte data shown are from profiling on the RBM Luminex platform, except for Fibrinogen which was tested at Hospital Grosshansdorf. COPD subjects were grouped as GOLD I/II (mild/moderate) and GOLD III/IV (severe/very severe). ANOVA was used for group-wise comparisons, except for analytes noted with *, which did not follow a normal distribution and a non-parametric Kruskal Wallis test was used.</p

Correlation network illustrating functional co-clustering of analytes associated with FEV₁, FEV₁/FVC and DLCO.

<p>Analytes are plotted in a network using Cytoscape <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0038629#pone.0038629-Shannon1" target="_blank">[83]</a> where nodes represent analytes and edges represent significant correlations (<i>r</i> >0.4, <i>p</i><0.05, corrected for multiple testing). Analytes are colored according to whether they were associated with FEV₁ related parameters (green), DLCO (red) or both DLCO and FEV₁ related parameters (orange) in univariate regression. Node size is proportional to the number of lung function parameters that showed significant association with a given analyte. Clusters of co-expressed analytes with similar function are highlighted by dotted regions in the graph as neutrophil function (orange), systemic inflammation (blue) and growth factor pathways (grey).</p

Association of MPO with FEV₁/FVC and Fibrinogen with DLCO in COPD patients with and without metabolic syndrome.

<p>Log2-transformed levels of MPO (A, C) and Fibrinogen (B, D) (ng/ml for MPO and mg/dl for Fibrinogen) are plotted against covariate adjusted values for FEV₁/FVC and DLCO, respectively in COPD patients with (A, B) and without (C, D) metabolic syndrome (<i>r</i> values indicate spearman correlation, covariates include age, sex, BMI, pack years and smoking status).</p